March 13, 2019

Harpoon Therapeutics to Participate in Upcoming William Blair Cancer Immunotherapy Conference

SOUTH SAN FRANCISCO, Calif., March 13, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in the William Blair Cancer Immunotherapy Conference on Wednesday, March 20 2019 at 1:30 p.m. ET in New York City. Dr. McMahon will be a speaker during “Session II, Bispecific Approaches” and will provide an overview of Harpoon’s proprietary Tri-specific T cell Activating Construct™ (TriTAC) technology and pipeline development programs.  

About Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct™ (TriTAC) platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.

Contacts

Harpoon Therapeutics, Inc.
Georgia Erbez
Chief Financial Officer
650-443-7400
media@harpoontx.com

Westwicke Partners, LLC.
Robert H. Uhl
Managing Director
858-356-5932
robert.uhl@westwicke.com

Harpoon_logo (002).jpg

Source: Harpoon Therapeutics

Search Investor Relations